Status:
COMPLETED
Effector and Regulatory T Cell Receptor Repertoire Analyses in Patients Affected by COVID-19
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
COVID-19
Eligibility:
All Genders
18-75 years
Brief Summary
The specificity of the adaptive immune response (AIR), and its balance between effector T cells (Teffs) and regulatory T cells (Tregs), is most likely a major determinant of the outcome of a Covid-19 ...
Detailed Description
The quality of the adaptive immune response (AIR) to COVID-19 probably determines the course of the disease. Therefore, a comprehensive knowledge of the immune response to COVID-19 is required to bett...
Eligibility Criteria
Inclusion
- Inclusion criteria :
- Age≥18 and ≤75 years
- Presenting a confirmed diagnosis of COVID-19 disease in accordance with WHO diagnostic criteria;
- Good venous capital ;
- Affiliation to a social security system;
- Having declared his/her non-opposition to participation in research (for patients hospitalized in intensive care units who are not able to communicate, the non-opposition of a trusted person will be sought.)
- Exclusion criteria :
- Still under the exclusion period from another biomedical study
- Psychiatric illness or addiction that could interfere with the ability to comply with the requirements of the protocol or to give consent to participate in the study;
- Patient benefiting from a legal protection measure
Exclusion
Key Trial Info
Start Date :
May 11 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 27 2021
Estimated Enrollment :
58 Patients enrolled
Trial Details
Trial ID
NCT04379466
Start Date
May 11 2020
End Date
January 27 2021
Last Update
June 13 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Pitie Salpétrère
Paris, France, 75013